These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8035035)

  • 41. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.
    Baxter R; Reisinger K; Block SL; Izu A; Odrljin T; Dull P
    J Pediatr; 2014 Jun; 164(6):1409-15.e4. PubMed ID: 24657122
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assignment of Neisseria meningitidis serogroups A, C, W135, and Y anticapsular total immunoglobulin G (IgG), IgG1, and IgG2 concentrations to reference sera.
    Joseph H; Balmer P; Bybel M; Papa T; Ryall R; Borrow R
    Clin Diagn Lab Immunol; 2004 Jan; 11(1):1-5. PubMed ID: 14715537
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
    Klein NP; Habanec T; Kosina P; Shah NR; Kolhe D; Miller JM; Hezareh M; Van der Wielen M
    Vaccine; 2018 Apr; 36(17):2356-2363. PubMed ID: 29576307
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies.
    Rosenqvist E; Høiby EA; Wedege E; Kusecek B; Achtman M
    J Infect Dis; 1993 May; 167(5):1065-73. PubMed ID: 8486938
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Seroprevalence and placental transmission of maternal antibodies specific for Neisseria meningitidis Serogroups A, C, Y and W135 and influence of maternal antibodies on the immune response to a primary course of MenACWY-CRM vaccine in the United Kingdom.
    Blanchard-Rohner G; Snape MD; Kelly DF; O'Connor D; John T; Kibwana E; Parks H; Ford K; Dull PM; Pollard AJ
    Pediatr Infect Dis J; 2013 Jul; 32(7):768-76. PubMed ID: 23538521
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization.
    Ceesay SJ; Allen SJ; Menon A; Todd JE; Cham K; Carlone GM; Turner SH; Gheesling LL; DeWitt W; Plikaytis BD
    J Infect Dis; 1993 May; 167(5):1212-6. PubMed ID: 8486957
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Humoral immune response to the proteins of an antimeningococcal BC vaccine in a trial carried out in Antioquia, Colombia].
    Echeverry Uribe ML; Malberty Agüero JA; Galeano Marín LA; Sotolongo Padrón FT; Galguera Domínguez MA; Montoya Barrientos CM; Blanco González R; Martínez Ruiz O; Martínez Fernández OM; Aguirre Muñoz CA
    Bol Oficina Sanit Panam; 1995 Apr; 118(4):285-94. PubMed ID: 7779283
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England.
    Ladhani SN; Giuliani MM; Biolchi A; Pizza M; Beebeejaun K; Lucidarme J; Findlow J; Ramsay ME; Borrow R
    Emerg Infect Dis; 2016 Feb; 22(2):309-11. PubMed ID: 26811872
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents.
    Baxter R; Reisinger K; Block SL; Percell S; Odrljin T; Dull PM; Smolenov I
    Pediatr Infect Dis J; 2014 Nov; 33(11):1169-76. PubMed ID: 24911896
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults.
    Konar M; Granoff DM
    Blood; 2017 Aug; 130(7):891-899. PubMed ID: 28630122
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Humoral immune response to the capsular polysaccharide of Neisseria meningitidis serogroup C in an antimeningococcal BC vaccination trial in Antioquia, Colombia].
    Echeverry Uribe ML; Malberty Agüero JA; Galeano Marín LA; Sotolongo Padrón FT; Galguera Domínguez MA; Montoya Barrientos CM; Martínez Ruiz O; Nerey MC; Camarasa MA; Bacallao Gallestey J
    Bol Oficina Sanit Panam; 1995 Apr; 118(4):295-301. PubMed ID: 7779284
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and immunogenicity of a tetravalent polysaccharide vaccine against meningococcal disease.
    Shao PL; Chang LY; Hsieh SM; Chang SC; Pan SC; Lu CY; Hsieh YC; Lee CY; Dobbelaere K; Boutriau D; Tang H; Bock HL; Huang LM
    J Formos Med Assoc; 2009 Jul; 108(7):539-47. PubMed ID: 19586827
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination.
    Block SL; Christensen S; Verma B; Xie F; Keshavan P; Dull PM; Smolenov I
    Vaccine; 2015 Apr; 33(18):2175-82. PubMed ID: 25744224
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Complement factor 7 gene mutations in relation to meningococcal infection and clinical recurrence of meningococcal disease.
    Kuijpers TW; Nguyen M; Hopman CT; Nieuwenhuys E; Dewald G; Lankester AC; Roos A; van der Ende A; Fijen C; de Boer M
    Mol Immunol; 2010 Jan; 47(4):671-7. PubMed ID: 19931914
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults.
    Lee HJ; Chung MH; Kim WJ; Hong YJ; Choi KM; Lee J; Oh CE; Welsch JA; Kim KH; Hong KB; Dagnew AF; Bock H; Dull PM; Odrljin T
    Int J Infect Dis; 2014 Nov; 28():204-10. PubMed ID: 25316331
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease.
    Idänpään-Heikkilä I; Høiby EA; Chattopadhyay P; Airaksinen U; Michaelsen TM; Wedege E
    J Med Microbiol; 1995 Nov; 43(5):335-43. PubMed ID: 7562997
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum antibodies to capsular polysaccharide vaccine of group A and C Neisseria meningitidis in military recruits in Italy.
    Occhionero M; Usai G; Di Martino M; Le Moli S; Stroffolini T; Mastrantonio P
    Allergol Immunopathol (Madr); 1991; 19(1):39-41. PubMed ID: 1950941
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immune Responses to Booster Vaccination With Meningococcal ABCWY Vaccine After Primary Vaccination With Either Investigational or Licensed Vaccines: A Phase 2 Randomized Study.
    Szenborn L; Block SL; Jackowska T; Konior R; D'Agostino D; Smolenov I; Toneatto D; Welsch JA
    Pediatr Infect Dis J; 2018 May; 37(5):475-482. PubMed ID: 29329168
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Opsonophagocytosis of fluorescent polystyrene beads coupled to Neisseria meningitidis serogroup A, C, Y, or W135 polysaccharide correlates with serum bactericidal activity.
    Martinez J; Pilishvili T; Barnard S; Caba J; Spear W; Romero-Steiner S; Carlone GM
    Clin Diagn Lab Immunol; 2002 Mar; 9(2):485-8. PubMed ID: 11874898
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococcal A/C polysaccharide vaccine.
    Borrow R; Richmond P; Kaczmarski EB; Iverson A; Martin SL; Findlow J; Acuna M; Longworth E; O'Connor R; Paul J; Miller E
    FEMS Immunol Med Microbiol; 2000 May; 28(1):79-85. PubMed ID: 10767611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.